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Introduction:  Inhibition of the Janus kinase (JAK)-signal transducer and activator 
of transcription (STAT) pathway has been implicated as a treatment option for 
extranodal NK/T-cell lymphoma, nasal type (NTCL). However, JAK-STAT pathway 
alterations in NTCL are variable, and the efficacy of JAK-STAT pathway inhibition 
has been poorly evaluated. 
Materials and Methods: JAK3 mutation and STAT3 genetic alterations were 
investigated by direct sequencing and immunohistochemistry in 84 patients with 
newly diagnosed NTCL. Novel JAK3 mutations were functionally validated using 
Ba/F3 and NIH-3T3 cells with retrovirus vector systems. A JAK3 homology model 
was constructed. Cell viability assays were performed using JAK3 or STAT3 
inhibitor in NTCL cells. 
 Results: Five (7.0%) of 71 NTCL patients had JAK3 mutations in the pseudokinase 
domain: 2 JAK3A573V, 2 JAK3H583Y, and 1 JAK3G589D mutation. Ba/F3 cells transduced 
with novel JAK3 mutations (JAK3H583Y and JAK3G589D) grew independently without 
IL-3. NIH-3T3 cells transduced novel JAK3 mutations showed anchorage 
independent growth in soft agar plate. The transduced Ba/F3 cells were inhibited by 
the JAK3 inhibitor tofacitinib (mean IC50, 85 ± 10nM and 54 ± 9nM). Ribbon 
diagrams showed that these JAK3 pseudokinase domain mutations were located at 
the pseudokinase-kinase domain interface. Although phosphorylated STAT3 was 
overexpressed in 35 (51.4%) of 68 NTCL patients, STAT3 mutation (p.Tyr640Phe; 
STAT3Y640F) at the SRC homology 2 domain was detected in 1 (1.5%) of 63 patients. 
A STAT3 inhibitor was active against STAT3-mutant SNK-6 and YT cells.  
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Conclusions: Novel JAK3-activating mutations are oncogenic and sensitive to a 
JAK3 inhibitor in NTCL. Although STAT3 mutation rate is low in NTCL patients, 
STAT3-mutant NTCL cells are sensitive to a STAT3 inhibitor. JAK3 or STAT3 signal 
was altered in NTCL and pathway inhibition might be a therapeutic option for 
patients with JAK3- or STAT3-mutant NTCL. 
 
* This work is published in Am J Pathol. 2017 May;187(5):980-986. 
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NK/T-cell lymphoma, nasal type (NTCL) is a subtype of Epstein-Barr virus 
(EBV)-positive and highly aggressive mature NK/T-cell neoplasm with extranodal 
presentation.1,2 The distribution of NTCL is geographically different, consisting of 
about 10% of all peripheral T cell lymphoma and about half of all mature T cell 
lymphoma in Asian countries.3 It also has unique clinical features being frequently 
localized in nasal cavity with tissue infiltration. The main treatment is combination 
of cytotoxic chemotherapy with or without radiation. Although the recent advances 
of treatment, the survival outcome of advanced disease is poor.4 Therefore, discovery 
of new druggable targets is critical.5 
 With the advances of understanding molecular mechanism, many genetic 
alterations have been discovered in cancer. However, few molecular mechanisms 
have been understood and identifying the key pathway for treatment target is a major 
challenge in NTCL. Recently, several reports shed light on the genetic mechanism 
that JAK-STAT pathway activation6-8 and other several novel oncogenes9,10 may be 
implicated in NK/T-cell lymphoma oncogenesis. JAK/STAT pathway is well known 
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in hematopoiesis process and immune regulation.11,12  
The frequency of JAK3 mutations or STAT3 alteration in NTCL has been 
variable. Several studies reported that JAK3 mutation or constitutive 
phosphorylation of STAT3 contribute to NK/T-cell lymphoma oncogenesis from 0 
up to 35.4% of patients.7,13,14 However, other reports using next-generation 
sequencing revealed a low JAK3 mutation frequency (0-5%).8-10  
A JAK3 inhibitor was shown to be effective against NK-S1 cells with the 
JAK3A572V mutation7 and against MEC04 cells with the JAK3A573V mutation13 in vitro 
and in vivo; however, its ability to inhibit other JAK3 mutant subtypes has not been 
elucidated. 
In this study, we explored JAK3 mutations and STAT3 alterations in NTCL 
and discovered novel JAK3-activating mutations. We further investigated if the 
novel mutations had oncogenic potential, and the JAK3 mutations or STAT3 





Materials and Methods 
Patients 
Eighty-four patients were newly diagnosed with NTCL based on the World 
Health Organization (WHO) classifications1,2 between January 2001 and December 
2011 at Seoul National University Hospital. Formalin-fixed, paraffin-embedded 
(FFPE) tissue samples were prepared and tested for JAK-STAT pathway alterations. 
This study was approved by the Institutional Review Board of Seoul National 
University Hospital (H1404-071-572). 
 
JAK3 and STAT3 genetic alterations 
 Direct sequencing of PCR products was performed bidirectionally to detect 
JAK3 mutations on exons 13 and 16 and STAT3 mutation on exon 21. Briefly, 
genomic DNA was isolated from FFPE tumor tissue using a Maxwell 16 FFPE Plus 
Tissue LEV DNA Purification kit (Promega, Madison, WI, USA). JAK3 and STAT3 
exons were amplified from genomic DNA using EconoTaq PLUS GREEN 2× 
premix (Lucigen, Middleton, WI, USA), and then sequenced bi-directionally using 
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the ABI3730 DNA sequencer (Applied Biosystems, Carlsbad, CA, USA). The 
primer pairs used in the present study were as follows: JAK3 A572V and A573V 
mutations on exon 13 (F: 5′-GCAGGTCTGTGAGCACAAAAT-3′, R: 5′-
ACTGTCTCC AGCCATGCAC ACG-3′), JAK3 V722I mutation on exon 16 (F: 5′-
AGGCGCAGACACTTAGCTTG-3′, R: 5′-CAA AGTGGGGGTTCGGAGAC-3′), 
and STAT3 Y640F and D661Y mutations on exon 21 (F: 5′-
TTTCCGAATGCCTCCTCCT TGG-3′, R: 5′-GAGA TGACCTAGCTGTAGGTT 
CC-3′). 
 
Retrovirus packaging and transduction 
 Retroviral vectors harboring novel JAK3 mutations were generated through 
site-directed mutagenesis, and were introduced into Ba/F3 and NIH-3T3 cells to test 
transformation capacity. The coding region of JAK3 (NM_000215.3) was amplified 
and cloned into vector TOPO TA (Invitrogen, Grand Island, NY, USA). Mutations 
of JAK3 with 1847 T > C and 1866 A > G in the coding region were created by site-
directed mutagenesis (Agilent Technologies, Santa Clara, CA, USA) with mutation-
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specific primers according to the manufacturer`s instructions. The Platinum-E 
retroviral packaging cell line was seeded in DMEM with 10% (v/v) FBS. The 
following day, the cells were transfected with the JAK3 mutant construct in the 
pMXs-Puro vector (Cellbio Labs, San Diego, CA, USA) and the packaging plasmids 
pCL-eco using Fugene6® transfection reagents (Roche, Indianapolis, IN, USA). 
Viral supernatants were collected 48-72h later. Ba/F3 and NIH-3T3 cells in 6-well 
plates or 10-cm dishes were inoculated with 1 ml viral supernatant in 1 ml medium 
with polybrene (4 μg/ml). The transduced cells were selected using puromycin. 
 
Soft agar assay 
 Cells were suspended in medium containing 0.3% select agar and plated on 
a bottom layer of medium containing 1% select agar [2% agar was melted in a 
microwave oven, mixed 1:1 with medium (2× DMEM medium with 20% FBS, 2% 
P/S mixture, and 2% glutamine)] in a 6-well plate. To enable colony formation, plates 
were incubated at 37°C for 2 weeks. The number of colonies that grew in the 6-well 




Immunohistochemistry and immunoblotting 
 Two-millimeter diameter core samples were taken from representative 
FFPE tissue blocks of patients’ tumors. Tumor cell content (%) was evaluated by 
board-certified pathologists (YKJ, SJN, and CWK) (Table 1). Immunohistochemical 
staining for phosphorylation of STAT3 (p-STAT3) was performed using anti-pSTAT3 
antibody (Cell Signaling Technology, Danvers, MA, USA). Part of the unstained 
tumor area was used as a negative staining control. Immunoreactivity was recorded 
as a total percentage (%) of positive cells for pSTAT3. Only tumor cells were counted; 
if the number of cells with strong nuclear staining for p-STAT3 was more than 2% 
of all tumor cells, then the tumor had a high level of expression. Antibodies to total 
STAT3 and phospho-STAT3 (Cell Signaling Technology) were used for Western 
blotting, and the blots were subsequently washed, transferred to membranes, and 





Cell culture and cell viability assay 
 SNK-6 and NKL cells were kindly provided by Drs. Norio Shimizu 
(Tokyo Medical and Dental University, Japan) and Masao Seto (Aichi Cancer Center, 
Japan), respectively. YT cells were purchased from the German Resource Center for 
Biological Material (DSMZ; Braunschweig, Germany). The JAK3 inhibitor 
tofacitinib or the STAT3 inhibitor Stattic was added to each well at specified 
concentrations (tofacitinib and Stattic, Selleck Chemical, Houston, TX, USA). The 
plates were incubated at 37°C in a 5% CO2 atmosphere incubator for 48 or 72 h. For 
Ba/F3 with tofacitinib, the cells were incubated without IL-3 for 72 h; for NTCL 
with Stattic, the cells were incubated without IL-2 for 48 h. Growth inhibition assays 
were assessed using the CCK-8 colorimetric assay (DOJINDO Laboratories, Japan). 
For IL-3-independent growth assays, Ba/F3 cells transfected with the JAK3 mutant 
plasmid were cultured in the absence of IL-3 for 6 days. The number of viable cells 





JAK3 homology modeling 
 A JAK3 homology model was constructed using the SWISS-MODEL 
server.15 TYK2 structure (Protein Data Bank ID: 4OLI)16 was used as the modeling 
template. The stereochemical quality of the constructed models was validated using 
a Ramachandran plot generated by PROCHECK. Ribbon diagrams were generated 




Mann Whitney U test was performed to compare differences of colony 
formation in soft agar. The differences in clinical characteristics according to the PD-
L1 expression were analyzed using Fisher’s exact test. Progression-free survival 
(PFS) was measured from the date of initiation of treatment to disease progression, 
death, or the last follow-up. Overall survival (OS) was measured from the date of 
diagnosis to death or the last follow-up. Survival was analyzed using Kaplan-Meier 
plots and was compared with the log-rank test. Cox proportional hazard regression 
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model was used to perform multivariate analysis. A P value less than 0.05 was 
considered to indicate statistical significance. All statistical analyses were performed 

















Patient characteristics  
 Tumor tissues from 84 NTCL patients were examined for the presence of 
JAK3 mutations within the pseudokinase domain (JH2) and STAT3 alterations 
(mutation within the SRC homology 2 domain and phosphorylation). All patients 
were EBV positve and about two-fifths of patinets were Ann Arbor stage III or IV 
(n=32). Approximately two-thirds of NTCL patients presented with involvement of 
the upper aerodigestive tract (n = 58), and two-fifths of patients presented with 










Table 1. Clinicopathologic Characteristics of Patients 
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Abbreviation : UAT, upper aerodigestive tract; NUAT, non-upper aerodigestive tract; 
ECOG, eastern cooperative oncology group; EBV, epstein-barr virus; IPI , 
international prognostic index. 
 
JAK3 mutations  
 We identified three JAK3 mutations on exon 13 in 5 (7.0%) of 71 patients 
who had amplified PCR products from FFPE tumor tissues. Tumor cell content 
ranged from 1% to 64%. The JAK3A573V mutation was identified in two patients with 
non-upper aerodigestive tract NTCL (Table 2).  The following two novel 
heterozygous missense mutations were identified in JAK3 exon 13: histidine-to-
tyrosine substitution at codon 583 (JAK3H583Y, c.1847C>T, NM_000215.3) (n = 2) 
and glycine-to-aspartic acid substitution at codon 589 (JAK3G589D, c.1866G>A) (n = 
1) (Figure 1A). Germ line JAK3 mutation status was not evaluable due to lac k of 
normal tissues or blood samples except patient #5. The sequencing of JAK3 in bone 
marrow sample showed no germ line JAK3 mutation (Figure 1B). Therefore, the 
JAK3G589D mutation was somatic. The JAK3 mutations in exon 16, such as JAK3V722I, 
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were not observed in 68 NTCL patients who had amplified PCR products from FFPE 
tumor tissues. Overall, the JAK3 mutation frequency in NTCL was 7.0% in our study 
(Figure 2)7-10,17,18. Ki-67 level was not different between mutation positive and 















Table 2. JAK3 or STAT3-mutant NTCL 
No. #1 #2 #3 #4 #5 #6 
Sex/age F/49 M/37 M/68 M/47 F/42 M/57 
Primary site NUAT NUAT NUAT UAT UAT UAT 
Stage I IV III IV I IV 
First line treatment CHOP IMEP CHOP BVP IMEP IMEP 
Response to 
treatment 
SD PD NA PD CR PD 
PFS(months) 4.07 2.43 NA 0.6 29.27 2.03 
OS(months) 11.67 2.83 NA 0.7 29.77 3.36 
Ki-67(%) 68 20 30 70 60 70 
JAK3 mutation A573V A573V H583Y H583Y G589D WT 
STAT3 mutation WT NA WT NA WT Y640F 
Phospho-STAT3 High Low Low Low Low Low 
Abbreviation : UAT, upper aerodigestive tract; NUAT, non-upper aerodigestive tract; 
NA, not available; WT, wild-type; CHOP, cyclophosphamide, doxorubicin, 
vincristine, prednisolone; IMEP, ifosfamide, methotrexate, etoposide, and 














Figure 1. Electropherogram of JAK3 and STAT3 mutation.  A. JAK3 mutation 
(patient #1-5) and STAT3 mutation (patient #6) in NTCL. B. Electropherogram of 
wild –type JAK3 in a normal bone marrow sample of Patieht#5(with G589D 
mutation). Sanger sequencing of JAK3 genomic DNA from bone marrow sample 






Study A572V A573V  H583Y G589D  V722I  JAK3 mutation (%) 
Koo et al.7 20/65 4/65  0/65 0/65 0/65  23/65 (35.4%) 
Bouchekioua et al.17 0/19 3/19 0/19 0/19 1/19  4/19 (21%) 
Kimura et al.18 0/17 0/17     0/17 (0%) 
Lee et al.10 2/39 0/39    2/39 (5.1%) 
Küçük et al.8 0/40 0/40 0/40 0/40 0/40 0/40 (0%) 
Jiang et al.9. 0/25 0/25 0/25 0/25 0/25 0/25 (0%) 
Present study 0/71 2/71  2/71 1/71 0/68 5/71 (7.0%) 
Sum (%) 22 (8.0) 9 (3.1) 2 (0.9) 1 (0.4) 1 (0.4) 34/276 (12.3) 










Oncogenic properties of novel JAK3 mutations 
 We constructed retroviral vectors expressing JAK3 wild type, or 
JAK3H583Y, JAK3G589D, or JAK3A572V mutations. Then we inoculated NIH-3T3 or 
Ba/F3 cells with these vectors. Ba/F3-JAK3H583Y and Ba/F3-JAK3G589D cells 
displayed IL-3-independent growth (Figure 3A), whereas NIH-3T3-JAK3H583Y and 
NIH-3T3-JAK3G589D cells displayed anchorage-independent growth (Figure 3B), 
similar to the transforming activity of JAK3A572V mutant cells.7,10 Then, we tested 
whether the JAK3 inhibitor tofacitinib could inhibit the growth of JAK3H583Y- and 
JAK3G589D-transduced Ba/F3 cells. Tofacitinib significantly inhibited Ba/F3-
JAK3H583Y and Ba/F3-JAK3G589D cell growth; it also inhibited Ba/F3-JAK3A572V 
























Figure 3. Oncogenic properties of novel JAK3 mutations and Cell viability assays 
with tofacitinib. A: IL-3-independent proliferation of Ba/F3 cells transduced with 
retrovirus containing JAK3 mutation. B: NIH-3T3-JAK3, NIH-3T3-A572V, NIH-
3T3-H583Y, and NIH-3T3-G589D cell growth was measured by colony formation 
in soft agar. C: Ba/F3-JAK3H583Y and Ba/F3-JAK3G589D cells were sensitive to 
the JAK3 inhibitor. IC50 values are provided for each case (μM). 









Structural modeling of novel JAK3 mutations 
 Ribbon diagrams of the JAK3 JH2 and kinase (JH1) domains showed that 
H583 in the αC-helix and G589 in the β4-sheet were located in the N-lobe of the JH2 
domain (Figure 4A), similar to other tumor-associated JAK3 JH2 mutations, such as 
A572V and A573V. The two mutations are located in the interface between the 
pseudokinase and kinase domains. The JAK3H583Y and JAK3G589D mutation sites were 














Figure 4. Homology models of JAK3 pseudokinase and kinase domain (A). H583Y 






STAT3 mutation and phosphorylation  
 Strong expression of phosphorylated STAT3 (p-STAT3) in the nucleus of 
≥2% of all tumor cells was observed in 35 (51.4%) of 68 patients (Figure 5). 
Although clinical variables were not significantly associated with p-STAT3 
expression, tumors with high p-STAT3 expression showed a trend toward better 
ECOG performance status but toward advanced disease stage (Table 3). The Kaplan-
Meier plot showed high pSTAT3 showed better survival but it was not statistically 
significant (P=0.137) (Figure 6). The univariate and multivariate analysis showed 
local invasion, ECOG performance status and IPI score was significantly associated 
















Figure 5. p-STAT3 in NTCL. Immunohistochemical staining for STAT3 
phosphorylation (p-STAT3) reveals low p-STAT3 (upper panel) and high p-STAT3 








Table 3. phospho-STAT3 and clinical characteristics 
  pSTAT3 high pSTAT3 low p 


















































Abbreviation : UAT, upper aerodigestive tract; NUAT, non-upper aerodigestive tract; 






Table 4. Univariate analysis of survival 
  Univariate analysis  
Variable  HR 95%CI P-value 
Age <65 
≥65 
0.784 0.301-2.042 0.618 
sex M 
F 
0.766 0.370-1.584 0.472 
Local invasion Yes 
No 
0.439 0.215-0.898 0.024 
Ki-67(<45 ) <45 
≥45 
0.831 0.510-2.315 0.831 
Ann Arbor Stage 0,1,2 
≥3 
3.558 1.688-7.500 0.001 
B Symptom Yes 
No 
0.270 0.129-0.564 0.001 
Primary tumor location UAT 
NUAT 
2.131 1.033-4.397 0.041 
ECOG(01 vs other) 0,1 
≥2 
9.211 4.375-19.394 0.001 
IPI (0,1,2 vs other) 0,1,2 
≥3 
6.690 3.043-14.706 0.001 




0.415 0.124-1.389 0.154 
pSTAT Positive 
Negative 
1.792 0.831-3.860 0.137 
Abbreviation : UAT, upper aerodigestive tract; NUAT, non-upper aerodigestive tract; 
ECOG, eastern cooperative oncology group; IPI , international prognostic index 
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Table 5. Multivariate analysis of survival   
Variable  HR 95%CI P-value 
Local invasion Yes 
No 
0.448 0.207-0.967 0.041 
ECOG(01 vs other) 0,1 
≥2 
4.332 1.915-9.801 0.001 
IPI (1,2 vs other) 1,2 
≥3 
4.538 1.869-11.018 0.001 








Figure 6. Kaplan-Meier plot according to pSTAT3. High pSTAT3 showed better 




STAT3 mutation (p.Tyr640Phe; STAT3Y640F) at the SRC homology 2 (SH2) domain 
was found in 1 (1.5%) of 63 tumor samples (Figure 7A). Growth of YT and SNK-6 
cells harboring STAT3Y640F and STAT3D661Y mutations, respectively, were inhibited by 
the STAT3 inhibitor Stattic (Figure 7B), but not by tofacitinib (Figure 7C). Stattic 
was not toxic to HANK1 cells with wild-type STAT3, which have relatively lower 
p-STAT3 (Tyr705) levels than SNK-6 and YT cells (Figure 7D). Diffuse large B-cell 
lymphoma cells without STAT3 mutation were used as controls; OCI-Ly3 cells with 
high p-STAT3 (Tyr705) expression were more sensitive to Stattic than SU-DHL6 





























Figure 7. STAT3 alteration and inhibition. A: Electropherogram of STAT3 mutation 
in patient #6, YT cells and SNK6 cells. B: Cell viability assay with various Stattic 
concentrations in NTCL cells. YT and SNK6 harboring STAT3 mutation were more 
sensitive to the STAT3 inhibitor than HANK1 or SU-DHL-6. Data are the mean ± 
standard deviation of three independent experiments. C: Cell viability assay with 
various tofacitinib concentrations in STAT3-mutant SNK-6 and YT cell lines. These 
were not sensitive to the tofacitinib. IC50 values were provided as mean ± standard 
deviation (μM). D: STAT3 phosphorylation status in various cell lines. OCI-Ly3 and 







 Our study demonstrated that JAK3-activating mutations were rare (7.0%) 
in patients with NTCL. We identified novel JAK3H583Yand JAK3G589D mutations that 
were oncogenic and targetable alterations. In addition, the STAT3 mutation in the 
SH2 domain also might be a promising target for inhibition as an NTCL treatment. 
 Since the first report of an oncogenic JAK3 mutation,7 reports of its 
mutation frequency in NTCL has been variable. In contrast to the studies reporting 
high mutation frequencies (21-35%),7,13 subsequent studies suggested a much lower 
mutation frequency ranging from 0% to 5.1%,8,10,18 which was comparable to our 
result (Figure 2). Although the JAK3A573V mutation (which is the second-most 
common) was identified in our patients, the JAK3A572V and JAK3V722I mutations were 
not observed, in contrast to previous reports.7,13 This difference in JAK3 mutation 
frequency might be attributable to the ethnic variation in NTCL. It is known that 
NTCL is heterogeneous and the incidence is variable according to geographic 
region.3,4 This suggests ethnic difference could be implicated in the different 
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mutation frequency.  In addition, technical issues in detecting mutations and 
variation in tumor content might have affected the results. Many cases of NK/T cell 
lymphoma have a high content of inflammatory cells, which might contribute to 
reported differences in mutation frequency. 
In this study, novel JAK3H583Y and JAK3G589D mutations with oncogenic 
potential that were somatic and not seen in COMSIC and public databases, were 
identified in three patients. Anchorage- or IL-3-independent growth of JAK3H583Y 
and JAK3G589D-mutant cells was observed in the NIH-3T3 or Ba/F3 cell lines, which 
suggested these novel JAK3 mutations had oncogenic properties. JAK3 mutant cells 
exhibited 6.2-46-fold greater sensitivity to tofacitinib compared to JAK3 wild-type 
cells. Considering the efficacy of tofacitinib for inhibiting JAK3 in Ba/F3-JAK3H583Y 
and JAK3G589D cells and inhibiting JAK3 through prevention of EZH2 
phosphorylation in NTCL,19 JAK3 inhibition might be clinically relevant for treating 
JAK3-mutant NTCL. In addition, structural modeling found that the novel JAK3 
mutations were located in the JAK3 pseudo-kinase domain. The novel JAK3 
mutations had closer proximity to the JH1 domain compared to the JAK3A572V and 
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JAK3A573V mutations, which might render the novel JAK3 mutations more oncogenic 
and sensitive to tofacitinib. These results suggested that novel JAK3 mutations in the 
N-lobe of the JH2 domain are druggable target oncogenes located at the interface of 
the JH2 and JH1 domains, similar to other cancer-associated JAK3 mutations.16 
Considering JH2-mediated negative regulation of JAK3,20 our pathogenic JAK3 
mutations in the JH2 domain might disrupt a negative signal between JH2-JH1 
domains, resulting in JAK3 kinase activation and sensitivity to inhibition.7 
Tofacitinib is a potent inhibitor of JAK1 and JAK3, but not JAK2, and has been used 
as monotherapy for treatment of rheumatoid arthritis.21 In addition, tofacitinib has 
shown clinical activities against JAK3-mutant primary mediastinal B-cell lymphoma 
as combination therapy22 and STAT3-mutant T-cell large granular lymphocytic 
leukemia as monotherapy.23 Clinical and in vitro activities of JAK3 inhibition 
warrant further investigation in JAK3-mutant lymphoid neoplasms including NTCL. 
STAT3 genetic alterations were evaluated because of the oncogenic role of 
constitutive STAT3 signal activation in NTCL.6,11 Although more than half of the 
patients showed strong p-STAT3 expression, the previously identified STAT3Y640F 
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mutation8-10,24 was found in only one patient, which was a relatively lower frequency 
than in other published studies (STAT3 mutation frequencies in the SH2 domain were 
reported as 5.9%,8 7.6%,9 and 26% 10). The several factors affecting STAT3 
phosphorylation and activation has been suggested, however, the exact mechanism 
of STAT3 phosphorylation in NTCL is not clear. Several studies reported that EBV 
associated protein such as LMP1 or EBNA2 could affect STAT3 activation in 
lymphoma.25,26 Other studies showed LEP fusion gene or loss of SH2B33 was 
associated with increase of p-STAT3.27 EZH2 phosphorylation was also associated 
with p-STAT3 in glioblastoma.28 STAT3 activation was adversely associated with 
survival in diffuse large B-cell lymphoma patients,29 whereas p-STAT3 did not 
correlate with survival in NTCL patients.  Stattic, a STAT3 inhibitor, was effective 
against STAT3-mutant NTCL cells, but less effective in STAT3-wild type NTCL cells 
with high p-STAT3 expression in our study. Similarly, NTCL patient-derived 
MEC04 cells with high p-STAT3 expression were inhibited by high concentrations 
of a STAT3 inhibitor.6 Interestingly, JAK1/2 inhibitors that disrupted the STAT3 
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activating signal inhibited NTCL cells with high p-STAT3 expression6 as well as 
STAT3-mutant NTCL cells,8 which suggested a therapeutic option for NTCL patients. 
 In conclusion, the frequency of JAK3 mutations in the JH2 domain was 
relatively low in NTCL (mean, 11.8%; range 0-35.4%) in contrast to a previous 
report.7 Here, we identified novel JAK3H583Y and JAK3G589D-activating mutations that 
were oncogenic and sensitive to a JAK3 inhibitor. Although the frequency of STAT3 
mutations was low in NTCL patients, STAT3-mutant NTCL cells were sensitive to a 
STAT3 inhibitor, but not to a JAK inhibitor. These results indicated that JAK3 and 
STAT3 mutations are candidate therapeutic targets in NTCL patients. Future efforts 
should be directed to evaluate the efficacy of JAK3 or STAT3 inhibitors in NTCL 
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서론: Janus kinase (JAK)- Signal trasnsducer and activator of 
transcription(STAT) 경로를 억제하는 것은 NK/T세포 림프종 치료법 
중 선택의 한가지로 고려되고 있다. 그러나, JAK-STAT 경로의 변화는 
다양하고, 해당 경로의 억제 효능은 제대로 평가되어 있지 않다. 본 연
구는 NK/T 세포 림프종에서, JAK3 유전자 돌연변이 및 STAT3 의 변
화를 탐색하고, 새로이 발견된 JAK3 유전자 돌연변이의 종양형성 가능
성을 평가하였다. 또한 JAK3 돌연변이 및 STAT3 의 변화가 치료약제
의 표적이 될 수 있는지를 평가하였다. 
방법 및 대상: NK/T 세포 림프종으로 새롭게 진단된, 84명 환자의 종양 
조직에서 직접적인 시퀀싱 및 면역조직 화학염색을 시행하여, JAK3 유
전자의 돌연변이 및 STAT3 유전자및 발현의 변화를 조사하였다. 새로
운 JAK3 유전자 돌연변이는, 레트로바이러스 벡터 시스템을 사용한 
Ba/F3 및 NIH-3T3세포주를 이용하여, 기능적 증명을 시행하였다. 또
한 JAK3 상동 구조 모델을 제작하여, 유전자의 구조적 위치를 파악하였
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다. NK/T 세포 림프종 세포주에서, JAK3 및 STAT3 억제제를 이용한 
세포 생존능력 분석을 시행하였다.  
결과:  71명의 NK/T 세포 림프종 환자 중, 5명(7.0%)에서, JAK3 유전
자의 pseudokinase 도메인에 돌연변이 ( JAK3A573V 2명,   JAK3H583Y 
2명,  JAK3G589D 1명)가 발견되었다. 새로운 JAK3 돌연변이(JAK3H583Y  
및  JAK3G589D)가 형질도입된 Ba/F3 세포주는 IL-3 와는 무관한, 독
립적인 증식이 관찰되었다.  같은 돌연변이 유전자가 형질도입된 NIN-
3T3 세포주는 soft agar plate 에서 비부착증식이 일어남을 확인하였다. 
새로운 돌연변이 유전자들이 형질도입 Ba/F3 세포주는 JAK3 억제제인 
tofacitinib을 처리하였을 경우, 세포 증식이 억제되었다(mean IC50, 85 ± 
10nM and 54 ± 9nM). 단백질 구조를 보여주는 리본 다이아그램(Ribbon 
diagram)에서, JAK3 pseudokinase 도메인에 위치한 JAK3 돌연변이들
은 pseudokinase-kinase 접촉면에 위치하는 것이 확인되었다.  인산화 
STAT3는 68명의 NK/T세포 림프종 환자중 35명(51.4%)에서 과발현
되어 있었으나, STAT3 유전자 돌연변이(p.Tyr640Phe; STAT3Y640F)는 
63명 중 1명(1.5%)에서 관찰되었다. STAT3 억제제는 STAT3돌연변
이가 존재하는 SNK-6 및 YT 세포주에서 활성이 있었다. 
결론: NK/T 세포 림프종에서, 새롭게 발견된 JAK3 활성 돌연변이는 종
양형성 능력을 가지고, JAK3 억제제에 효과적으로 반응한다. STAT3 돌
연변이 비율은 NK/T 세포 림프종에서 낮으나, STAT3-돌연변이 
NK/T 림프종 세포주는 STAT3 억제제에 효과적으로 증식이 억제되었
다..  JAK3 및 STAT3 신호 경로는 NK/T 세로 림프종에서 변형이 있
으며, 해당 경로 억제제는 JAK3 및 STAT3 돌연변이가 있는 환자에서 
선택 가능한 치료방법이 될 수 있다.  
* 본 내용은 American Journal of pathology 2017 May;187(5):980-
986 에 출판된 내용임
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